The Canadian Cancer Trials Group (CCTG) is pleased to announce that our Director, Dr. Janet Dancey, has been elected to the Canadian Academy of Health Sciences (CAHS), which represents Canadian health sciences internationally and informs solutions that improve the health of all Canadians.
Published: September 23, 2020
The results for the CCTG PA7 trial were recently presented at the European Society for Medical Oncology (ESMO) virtual Congress. The CCTG lead for this study, Dr. Daniel Renouf, reported on key results of the PA7 Randomized Phase II Trial of Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma Randomized Phase II Study of Gemcitabine (GEM) and Nab-Paclitaxel (Nab-P) vs. GEM, Nab-P, Durvalumab (D) and Tremelimumab (T) as First Line study.
CCTG would like to extend condolences to the family, friends, and colleagues of Dr. Libni Joseph Eapen who passed suddenly last week. Dr. Eapen was a researcher and radiation oncologist at the Ottawa Cancer Centre for the entirety of his career, he dedicated his 66 years to learning, teaching, humour and healing.
Published: September 09, 2020
OV19: A Randomized, Two-Arm, Multi-Centre Gynecologic Cancer Intergroup Trial of Adding Bevacizumab to Standard Chemotherapy (Carboplatin and Paclitaxel) In Patients with Epithelial Ovarian Cancer
JBR10: Immunohistochemical validation study of 15-gene biomarker panel predictive of benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of JBR.10
MAP3: A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer
CE6: A Randomized Phase III Study Of Temozolomide and Short-Course Radiation Versus Short-Course Radiation Alone in the Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients
BR18: A Phase II/III Double Blind Randomized Trial of BMS-275291 Versus Placebo in Patients Receiving Paclitaxel/Carboplatin Chemotherapy for the Treatment of
Advanced or Metastatic Non-Small Cell Lung Cancer